A Novel Technique for Repositioning of a Migrated ILUVIEN® (Fluocinolone Acetonide) Implant into the Anterior Chamber

Ophthalmology and Therapy

Volumn 4, Issue 2, 2015, Pages 129-133

  El Ghrably, Ibraheem A ^a   Saad, Ahmed ^a   Dinah, Christiana ^a  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Chronic diabetic macular edema; Fluocinolone acetonide; ILUVIEN; Intravitreal implant; Steroid implant migration

Indexed keywords

BEVACIZUMAB; FLUOCINOLONE ACETONIDE;

AGED; ANTERIOR EYE CHAMBER; ARTICLE; CASE REPORT; CENTRAL MACULA THICKNESS; CORNEA EDEMA; DIABETIC MACULAR EDEMA; FLUTE NEEDLE; FOLLOW UP; HUMAN; IMPLANT DISLOCATION; IMPLANT REPOSITIONING; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; LENS IMPLANT; LENS LUXATION; MALE; MEDICAL DEVICE COMPLICATION; MEDICAL PROCEDURES; OPHTHALMIC ASPIRATION NEEDLE; OPTICAL COHERENCE TOMOGRAPHY; PHACOEMULSIFICATION; PRIORITY JOURNAL; SLIT LAMP; SURGICAL TECHNIQUE; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; VITRECTOMY;

EID: 84958747829     PISSN: 21938245     EISSN: 21936528     Source Type: Journal    
DOI: 10.1007/s40123-015-0035-1     Document Type: Article

References (10)

1. Summary of product characteristics for ILUVIEN 190 micrograms intravitreal implant in applicator. https://www.medicines.org.uk/emc/medicine/27636. Accessed Apr 27, 2015.
2. NICE technology appraisals [TA301]. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271). 2013. https://www.nice.org.uk/guidance/ta301. Accessed Apr 27, 2015.
3. Ragam AP, Kolomeyer AM, Nayak NV, Chu DS. The use of ozurdex (dexamethasone intravitreal implant) during anterior segment surgery in patients with chronic recurrent uveitis. J Ocul Pharmacol Ther. 2015. doi:10.1089/jop.2015.0009.
4. Kocak N, Ozturk T, Karahan E, Kaynak S. Anterior migration of dexamethasone implant in a pseudophakic patient with intact posterior capsule. Indian J Ophthalmol. 2014;62(11):1086–8.
5. Collet B. Management of ozurdex in the anterior chamber. JAMA Ophthalmol. 2013;131(12):1651–2.
6. Khurana RN, Appa SN, McCannel CA, Elman MJ, Wittenberg SE, Parks DJ, Ahmad S, Yeh S. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology. 2014;121(1):67–71.
7. Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane FE, FAMOUS Study Group. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–7.
8. Summary of product characteristics for OZURDEX 700 micrograms intravitreal implant in applicator. https://www.medicines.org.uk/emc/medicine/23422. Accessed Apr 27, 2015.
9. Almeida DR, Chin EK, Mears K, Russell SR, Mahajan VB. Spontaneous dislocation of a fluocinolone acetonide implant (retisert) into the anterior chamber and its successful extraction in sympathetic ophthalmia. Retin Cases Brief Rep. 2015;9(2):142–4.
10. Costagliola C, Romano V, Forbice E, Angi M, Pascotto A, Boccia T, Semeraro F. Corneal oedema and its medical treatment. Clin Exp Optom. 2013;96(6):529–35.